TransCode Therapeutics (NASDAQ: RNAZ), a clinical-stage biopharmaceutical company developing RNA-based therapeutics and immuno-oncology treatments for high-risk and advanced cancers, announced that its board of directors has initiated a formal strategic process to evaluate opportunities to maximize the value of the company and its oncology portfolio, including lead product candidate TTX-MC138. The review will consider potential licensing or sales of individual assets, development and commercialization partnerships, portfolio transactions, business combinations and other strategic alternatives. TransCode has engaged Tungsten Advisors as its exclusive strategic financial adviser for the process.
TTX-MC138, an investigational RNA-based therapeutic targeting microRNA-10b, has advanced into Phase 2a clinical development following a Phase 1a study that provided initial safety data and reports of stable disease. The ongoing trial is evaluating the treatment in patients with circulating tumor DNA-positive colorectal cancer following curative-intent therapy, in collaboration with Quantum Leap Healthcare Collaborative. TransCode also recently announced a collaboration with Natera Inc. to use its Signatera test to identify eligible patients and support trial enrollment.
Chairman and CEO Philippe P. Calais said the strategic review is intended to identify opportunities to advance the company’s oncology programs while seeking to maximize stockholder value. TransCode cautioned that the process may not result in a transaction or other strategic outcome. To view the full press release, visit https://ibn.fm/AGxas.
The announcement signals a potential shift in strategy for TransCode, which is pioneering immuno-oncology and RNA therapeutic treatments for high-risk and advanced cancers. The company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors that overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells. The latest news and updates relating to RNAZ are available in the company’s newsroom at https://ibn.fm/RNAZ.
The strategic review could lead to significant implications for stakeholders. Licensing or selling individual assets might provide non-dilutive funding to advance other programs. Partnerships or business combinations could offer resources and expertise to accelerate development. However, the company’s caution that the process may not result in a transaction underscores the uncertainty. Investors and industry observers will be watching closely for any outcomes, as the review may reshape TransCode’s future and impact the broader oncology landscape.
The announcement was disseminated through BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences and life sciences sectors. BioMedWire is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which delivers wire solutions via InvestorWire and editorial syndication to 5,000+ outlets, among other services.
